Shots:
- The EC has approved perioperative Imfinzi regimen to treat resectable NSCLC adults at high risk of recurrence & no EGFR mutations or ALK rearrangements; MAA under PMDA review
- Approval was based on P-III (AEGEAN) trial assessing neoadj. Imfinzi (1500mg; Q3W × 4 cycles) + CT followed by adj. Imfinzi alone (Q4W × ~12 cycles) vs PBO in operable stage IIA-IIIB NSCLC pts (n=802), regardless of PD-L1 expression
- Trial showed 32% risk reduction in recurrence, progression, or death in interim EFS analysis (32% maturity), with final pCR analysis showing improved pCR rate (17.2% vs 4.3%). Interim OS data (35% maturity) presented at WCLC 2024 showed favorable trend, (mOS: not reached vs 53.2mos) & is still under assessment
Ref: AstraZeneca | Image: AstraZeneca
Related News:- Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
